Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $14.4 million.

  • Anika Therapeutics' Accumulated Expenses fell 23.18% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 23.18%. This contributed to the annual value of $13.6 million for FY2024, which is 3.55% down from last year.
  • Per Anika Therapeutics' latest filing, its Accumulated Expenses stood at $14.4 million for Q3 2025, which was up 26.94% from $11.3 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Accumulated Expenses ranged from a high of $19.8 million in Q3 2023 and a low of $11.3 million during Q2 2025.
  • Moreover, its 3-year median value for Accumulated Expenses was $15.5 million (2023), whereas its average is $15.8 million.
  • In the last 5 years, Anika Therapeutics' Accumulated Expenses increased by 29.62% in 2023 and then slumped by 31.53% in 2025.
  • Anika Therapeutics' Accumulated Expenses (Quarterly) stood at $17.8 million in 2021, then increased by 5.56% to $18.8 million in 2022, then declined by 25.34% to $14.1 million in 2023, then dropped by 3.55% to $13.6 million in 2024, then declined by 23.18% to $14.4 million in 2025.
  • Its Accumulated Expenses was $14.4 million in Q3 2025, compared to $11.3 million in Q2 2025 and $12.6 million in Q1 2025.